Scarica l'app Stockscreener
3.02
3.07%
0.09
Dopo l'orario di chiusura:
3.08
0.06
+1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eledon Pharmaceuticals Inc Borsa (ELDN) Ultime notizie
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart - marketscreener.com
Eledon submits IND for tegoprubart islet cell transplant study - Investing.com
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceNAAIM Leverage - dars.gov.et
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureMerger Arbitrage - vinanet.vn
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - vinanet.vn
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - vinanet.vn
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - vinanet.vn
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesLong-Term Guidance - vinanet.vn
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsIron Condor Alert - vinanet.vn
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock DeclinesRevenue Guidance Update - vinanet.vn
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADAR1 Capital Management LLC Has $3 Million Position in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Cash Flow - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - Sahm
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant Investing - TipRanks
Eledon Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesTax Rate Impact - vinanet.vn
ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw - Investing.com Canada
Eledon Pharmaceuticals (ELDN) Drops 7.5%: Key Support Tested Amid Biotech VolatilitySymmetrical Triangle - dars.gov.et
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Sahm
Eledon Pharmaceuticals (ELDN) Edges Higher as Stock Approaches Key Resistance at $4.15Leading Diagonal - dars.gov.et
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Price to earnings forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - Sahm
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):